Implant Sciences' QS-B220 Successfully Passes QT&E Portion of Checkpoint and Checked Baggage Qualification
Share:
QS-B220 is the first ETD with non-radioactive source to successfully complete the test and evaluation phase at TSA's Transportation Systems Integration Facility
WILMINGTON, Mass. - Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detection system has successfully completed and passed testing requirements of the Qualification Testing and Evaluation (QT&E) portion of the Transportation Security Administration's (TSA) Explosive Trace Detection (ETD) qualification test at the Transportation Systems Integration Facility (TSIF).
TSA's state-of-the-art TSIF, located at Ronald Reagan Washington National Airport, is where new screening technologies are tested before they are deployed to airports around the country. The facility provides an operational airport environment where TSA evaluates the technology by its concepts of operation, measures of performance, and measures of effectiveness.
In July 2013, the QS-B220 successfully completed the first step of QT&E, called Independent Testing and Evaluation (IT&E). QS-B220 has since passed the second step of QT&E at the TSIF, thereby fulfilling another important step towards qualifying the QS-B220 by the Transportation Security Administration and for use in major airports all across the US.
"Evaluation of our QS-B220 was a very important achievement that demonstrates the benefits of our ETD technology in action. The QS-B220 provides superior detection capabilities, a non-radioactive source, and operational and cost efficiencies that can deliver benefits at airport security checkpoints each year. The combination of enhanced performance and operational capabilities of the QS-B220 truly define the new standard of trace detection," stated Glenn D. Bolduc, Implant Sciences' President and CEO.
"Successfully completing QT&E brings us another step closer to completing TSA's Qualified Product List process, and we are confident that the QS-B220 will meet the remaining stringent testing requirements," added Dr. Darryl Jones, Vice President of Sales and Marketing at Implant Sciences.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. As of January 2013, the Company is only the third ETD manufacturer, and the first American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700Â Â Â Â Â Â
SourceÂ
Implant Sciences Corporation
Contact: Implant Sciences Corporation, Company Contact: Glenn Bolduc, CEO, 978-752-1700, gbolduc@implantsciences.com
Web Site: http://www.implantsciences.com
